The prevalence, the prognostic effect, and interaction with other molecular markers of DNMT3A mutations was studied in 415 patients with acute myeloid leukemia (AML) younger than 60 years. We show mutations in DNMT3A 
Introduction
Acute myeloid leukemia (AML) is a heterogeneous group of malignancies with different clinical behavior and different responses to therapy. AML can be classified according to distinct cytogenetic and genetic abnormalities, as well as on epigenetic differences that have been shown to be invaluable to guide risk assessment and choice of treatment. [1] [2] [3] Although insight into the disease has improved in past years, the discovery and validation of new discriminative biomarkers remain of utmost value to improve outcome prediction, in particular for those patients who cannot be classified yet with the currently available biomarkers.
The effect of the association between DNA methylation and various types of human cancer has become a main research domain over the past decade. In conjunction with other epigenetic processes such as histone modifications and interfering RNA, DNA methylation represents an essential component of the transcriptional regulation machinery 4 and of the repressive chromatin structure. 5 According to their structure in mammals, 3 families of DNA methyltransferase enzymes have been identified. 6, 7 They are related to each other and probably diverged early in eukaryotic evolution. 7 Mammalian DNA methyltransferases (DNMTs) catalyze the transfer of a methyl group onto the 5Ј-position of cytosine at CpG dinucleotides. 8, 9 DNMT3A and DNMT3B catalyze de novo DNA methylation, whereas DNMT1 is primarily responsible for maintenance methylation. 4, 7, [10] [11] [12] Recently, a somatic change in DNMT3A was identified in human AML, resulting in Arg-to-His substitution at codon R882, located in the methyltransferase domain, causing loss of methylation activity. 13 Recurrent DNMT3A mutations at multiple sites, including codon R882, were subsequently detected in a large cohort of patients with AML. [14] [15] [16] DNMT3A mutations were reported to frequently occur in AML with a normal karyotype and associated with French-American-British (FAB) M5 morphology. [14] [15] [16] An association with unique DNA methylation and gene expression profiles 16 and unfavorable prognosis were suggested. 15 In this study we investigated the distribution of DNMT3A mutations in a cohort of 415 AML cases. The relation with cytogenetic and molecular risk categories and the effect of DNMT3A mutations on treatment outcome were analyzed, and the association of DNMT3A mutations with gene methylation and gene expression patterns in AML was investigated. We provide evidence that the DNMT3A mutation status in AML is an important factor to consider for risk stratification of the disease.
Methods
Patients and patient samples and mutation analysis BM aspirates of patients with AML were collected after written informed consent in accordance with the Declaration of Helsinki. All experiments described were approved by the Erasmus University Medical Center Institutional Review Board. Patients with AML were treated according to the HOVON (Dutch-Belgian Hematology-Oncology Cooperative Group) AML protocols HO04, HO04A, HO29, HO42, HO42A, and HO43 (http://www.hovon.nl). Molecular aberrations in FLT3 (internal tandem duplication [ITD] or tyrosine kinase domain), NPM1, NRAS, KRAS, IDH1-2, KIT, WT1, and CEBPA and EVI1 overexpression were determined as described previously [17] [18] [19] [20] [21] 
DNMT3A mutation analysis
It was recently reported that most mutations in DNMT3A occurred in the second part of the gene. [14] [15] [16] Therefore, DNMT3A mutations were determined in the present study by cDNA amplifications with the use of FWA, 5Ј-ACGACAGCGATGAGAGTGAC-3Ј, and REVA, 5Ј-CCCAATCACCA-GATCGAATG-3Ј, or FWC, 5Ј-TGAGGACTCCATCACGGTG-3Ј, and REVC, 5Ј-CGGTATTTCCGCCTCTGTG-3Ј. All PCRs were performed in the presence of 25mM deoxynucleoside triphosphate, 20 pmol primers, 1mM MgCl 2 , Taq polymerase, DMSO, and 10 times buffer (Invitrogen). Cycling conditions were as follows: 1 cycle for 5 minutes at 94°C, 35 cycles for 1 minute at 94°C, 1 minute at 56°C, 1 minute at 72°C, and 1 cycle for 10 minutes at 72°C. All PCR products were subsequently sequenced with the appropriate primers (FWA, 5Ј-ACGACAGCGAT-GAGAGTGAC-3Ј, and FWB, 5Ј-GCTTTCTGGAGTGTGCGTAC-3Ј, or FWC, 5Ј-TGAGGACTCCATCACGGTG-3Ј, and FWD, 5Ј-TGATTGAT-GCCAAAGAAGTGTC-3Ј) applying an ABI-PRISM3100 genetic analyzer (Applied Biosystems). DNMT3A mutations are considered new somatic mutations in cases in which they were not reported as single nucleotide polymorphism (SNP) according to dbSNP version 132. DNMT3A mutations in AML around the hotspot site (R882) were confirmed by cDNA amplifications with FWD, 5Ј-TGATTGATGCCAAAGAAGTGTC-3Ј, and REVE, 5Ј-GACTGGCACGCTCCATGAC-3Ј, followed by denaturing HPLC analyses with the use of a Transgenomic WAVE system. Products were run at 60.4°C.
Gene expression profiling and methylation profiling
All AML cases were previously profiled for gene expression 22 (Gene Expression Omnibus; National Center for Biotechnology Information; www.ncbi.nlm.nih.gov/geo; accession no. GSE6891) and profiled for methylation 1 (accession no. GSE18700). For gene expression-based or gene methylation-based classification of DNMT3A in different defined intermediate risk subtypes, gene expression profiling and DNA methylation profiling (HpaII tiny fragment enrichment by ligation-mediated PCR) data of the HOVON cohort were used to derive predictive signatures with the use of a logistic regression model with Lasso regularization as reported previously. 23 
Statistics and survival analyses
The relation between DNMT3A mutations and various patient characteristics was determined by the chi square test or Fisher exact test for the categorical variables and by the Mann-Whitney U test for continuous variables. We distinguished the following cytogenetic risk categories: (1) favorable: t(8;21) or inv(16); (2) adverse: inv(3)/t(3,3), t(6;9), 11q23 abnormalities other than t(9;11), del5, del5(q), del7, del7(q), or t(9;22) and monosomal karyotypes 24 
Results

DNMT3A is frequently mutated in AML
We performed mutation analysis of the second part of DNMT3A, encompassing the PHD and methyltransferase domains, in 415 patients with newly diagnosed AML. This part of the gene, which has been reported to harbor Ͼ 95% of the mutations found in DNMT3A, represents exons 11 until the last exon, that is, exon 23. We found mutations in 96 of the 415 patients (23.1%), that is, 58 missense mutations at position R882 and 38 mutations at other positions (supplemental Figure 1 and supplemental Table 1 , available on the Blood Web site; see the Supplemental Materials link at the top of the online article). In 2 AML cases 2 DNMT3A mutations were found simultaneously (supplemental Table 1 ). All DNMT3A mutations were considered somatic according to dbSNP (version 132). Patients with AML with DNMT3A mutations presented with significantly higher age, higher white blood cell (WBC) counts, and higher platelet counts compared with DNMT3A wild-type AMLs (Table 1 ). In line with previous reports, 37.5% of FAB M5 AMLs (36 of 100) carried mutations in DNMT3A. Seventy-two of 96 DNMT3A mutant AMLs (75%) carried a normal karyotype (NK-AML). AMLs with t(8;21), inv (16) , inv(3; 3)/t(3,3), and trisomy 21 never carried DNMT3A mutations. Furthermore, DNMT3A mutations were rare in complex karyotype AMLs (Table 1) . We also separately analyzed 25 patients with acute promyelocytic leukemia (APL), that is, with a t(15;17), and found only 1 patient with a DNMT3A mutation (R882; supplemental Table 1 ).
DNMT3A mutations significantly associated with ITDs in FLT3 (FLT3 ITD ; P ϭ .002) as well as with mutations in NPM1 (P Ͻ .001) or IDH1 (P Ͻ .001). In contrast, DNMT3A mutations were significantly underrepresented in EVI1-overexpressing AMLs. The presence of DNMT3A mutations did not correlate with recurrent mutations in CEBPA, NRAS, KRAS, WT1, FLT3 (TKD), or KIT ( Table 1) .
The frequency of mutations in DNMT3A in patients with AML Ͼ 60 years, which were analyzed separately, was 10 of 63 (16%; supplemental Table 1 ). Four of 16 AMLs with myelodysplastic syndrome-related changes carried DNMT3A mutations. Mutations in DNMT3A were also found in 2 of 11 therapy-related AML cases (supplemental Table 1 ).
DNMT3A mutant is an independent prognostic marker in AML
The median follow-up of the 415 patients with AML that remained alive was 115.7 months (range, 7.2-224.1 months). The median OS of patients with DNMT3A mutant AML was shorter than that of patients with DNMT3A wild-type AML (11.9 months vs 24.0 months). DNMT3A mutant AMLs did not show a significantly different CR rate compared with patients with DNMT3A wild-type AML (ie, 88.54% for DNMT3A mutant vs 79.3% for DNMT3A wild-type AML; P ϭ .058). The univariate Cox regression analysis showed that the presence of DNMT3A mutation is an unfavorable prognostic factor for OS (P ϭ .022; hazard ratio [HR], 1.38; 95% confidence interval [CI],1.04-1.81) and RFS (P ϭ .005; HR, 1.52; 95% CI, 1.13-2.05) among all patients with AML ( Figure 1A-B) .
Multivariate analysis showed that DNMT3A mutant is an independent prognostic indicator for unfavorable OS (P ϭ .003; HR, 1.82; 95% CI, 1. (Table 2) . DNMT3A mutant showed no independent prognostic value for CR in multivariate analyses.
To investigate whether allogeneic transplantation modifies the prognostic effect of DNMT3A mutant , we applied Cox proportional hazards model with DNMT3A and allogeneic transplantation as a time-dependent covariate, including also an interaction of the 2. For overall survival, we observed a HR of 1.3507 (P ϭ .066; 95% CI, 0.98-1.86) for DNMT3A mutant . The interaction term with allogeneic transplantation was not significant (P ϭ .615; HR, 1.173; 95% CI, 0.623-2.189).
When we analyzed DNMT3A mutations at position R882 only, we observed an association with inferior outcome as well, that is, OS (P ϭ .018; HR, 1.49; 95% CI, 1.07-2.07) and RFS (P ϭ .029; HR, 1.50; 95% CI, 1.04-2.15) in this series of patients with AML (supplemental Figure 2A-B) . Figure 2A ; supplemental Figure 3A Figure 2B ; supplemental Figure 3B ), whereas DNMT3A mutations had no predictive value in the NPM1 mutant /FLT3 wild-type and the NPM1 mutant /FLT ITD subgroups ( Table 3 ). The predictive value for inferior OS (P ϭ .002; HR, 2.268; 95% CI, 1.36-3.79) and RFS (P ϭ .002; HR, 2.503; 95% CI, 1.42-4.42) was also evident in the NPM1 wild-type /FLT3 wild-type /CEBPA wild-type (no CEBPA DM ) subset ( Figure 2C ; supplemental Figure 3C ).
Because DNMT3A mutations were most frequently found in intermediate-risk AMLs (Table 1) , we performed the same survival analyses in subgroups within this particular subset, with comparable results (Table  3 ). In the FLT3 wild-type /NPM1 wild-type intermediate-risk AMLs, DNMT3A mutations were significantly associated with an inferior OS (P ϭ .013; HR, 2.09; 95% CI, 1.16-3.77) and RFS (P ϭ .001; HR, 2.70; 95% CI, 1.48-4.89; Figure 2E ; supplemental Figure 3E) Figure 2F ; supplemental Figure 3F ). We recently reported that IDH1 mutations have prognostic value in FLT3 wild-type /NPM1 wild-type as well. 21 Although the numbers were too low for a reliable statistical analysis, the high hazard ratios (Table 3) favor the hypothesis that the predictive value of DNMT3A mutations is independent of the presence of IDH1 and IDH2 mutations as well. We investigated whether DNMT3A mutant AMLs were associated with unique DNA methylation 25 or gene expression signatures. 22 Although DNMT3A mutant AMLs did not express a exclusive methylation signature, as determined with the HELP assay 25 (Figure 3 ), methylation cluster 13 was enriched for DNMT3A mutant AMLs (71.1% [n ϭ 32 of 45] DNMT3A mutant AML; Figure 3 ). Importantly, this cluster mainly contains FAB M4/M5 NPM1 mutant /FLT3 ITD AMLs. 25 This group of AMLs also showed a unique gene expression signature (supplemental Figure 4) . In fact, patient samples within this cluster overexpress multiple HOX genes, a signature that is particularly associated with NPM1 mutant AMLs. 20, 26, 27 It has been proposed that the increased levels of HOX genes in these leukemias are caused by loss of methylation as the result of mutations in DNMT3A 16 . However, we observed no difference in HOX gene expression, for example, HOXB5 expression levels between NPM1 mutant /DNMT3A mutant and NPM1 mutant /DNMT3A wild-type AMLs (supplemental Figure 5) . Thus, HOXB5 overexpression, representative for the expression of multiple HOX genes in human AML, does not associate specifically with the presence of DNMT3A mutations.
Supervised analysis with the use of a logistic regression model with Lasso regularization was performed to compare the gene expression as well as the gene methylation signatures of DNMT3A mutant versus DNMT3A wild-type AMLs in distinct subgroups, that is, in NPM1 mutant , FLT3 ITD , NPM1 mutant /FLT3 ITD , NPM1 wild-type / FLT3 ITD , NPM1 mutant /FLT3 wild-type , and NPM1 wild-type /FLT3 wild-type AMLs. We did not find a strong predictive signature for each dataset in any of the aforementioned AML subtypes within the intermediate risk group. Therefore, the role of mutated DNMT3A on DNA methylation and gene expression in human AMLs remains elusive.
Discussion
In this study, we identified mutations in DNMT3A in 96 of 415 newly diagnosed AMLs (23.1%). Of the 96 DNMT3A mutant AMLs, 85 belonged to the group of AMLs with an intermediaterisk cytogenetic profile. In fact, mutations in DNMT3A are as frequent in this group of AMLs as other common molecular abnormalities, such as mutations in FLT3 (FLT3 ITD ), NPM1, IDH1, or IDH2. As a matter of fact, DNMT3A mutations frequently are associated with these particular mutations, which is in strong concordance with data reported previously. [14] [15] [16] Note that, with the use of th approach we chose to determine mutations in DNMT3A, a small number of DNMT3A mutant AMLs may have been missed. We performed mutation analysis on cDNA in the second half of the DNMT3A gene only, that is, the region containing the PDH and methyltransferase domains and which, according to previous studies, harbors Ͼ 95% of the DNMT3A mutations. [14] [15] [16] Missense or frameshift mutations, leading to nonsense-mediated RNA decay, which represented only a minority of the mutations in previous studies, may have been missed as well because we used cDNA for nucleotide sequencing. However, the mutation rate we found is comparable with frequencies reported by others, suggesting that we identified most DNMT3A mutations in our cohort of AMLs and that the conclusions drawn in our study are valid.
Patients with DNMT3A mutant have significantly worse OS than patients with DNMT3A wild-type , independent of a number of NPM1, FLT3, or CEBPA mutations, and regardless of age, cytogenetic risk, and WBC count. Interestingly, by univariate analyses we show that in a composite genotypic subset of cytogenetic intermediate-risk AML without FLT3 ITDs and NPM1 mutations this association was particularly evident (OS, P ϭ .013; RFS, P ϭ .001). A negative prognostic effect of DNMT3A mutations on AML with a NK and with wild-type NPM1 and wild-type FLT3 was previously reported by Thol et al, 15 emphasizing the relevance of this finding. Similar to For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From Mutations in DNMT3A would predict that those AML cases show a distinct DNA methylation pattern than cases without mutations. Yan et al reported that DNMT3A mutations caused loss of methylase activity, and they proposed that these alterations resulted in hypomethylation and uncontrolled expression of multiple HOX genes. 16 Although we showed that DNMT3A mutant AMLs did not show a strong methylation signature, one methylation cluster (cluster 13) showed enrichment of DNMT3A mutant cases (Figure 3) . 25 Importantly, this cluster had already been reported to mainly consist of FAB M4/M5 AMLs with NPM1 mutant /FLT3 ITD . 1, 20 Moreover, this group of patients also showed a unique gene expression signature, including overexpression of multiple HOX genes. 20, 26, 27 Therefore, the question should be raised whether this HOX gene signature, that is, the strong increase of expression of multiple HOX genes, is indeed caused by hypomethylation of the HOX gene promoters as the result of mutations in the DNMT3A gene, as was reported by Yan et al. 16 Multiple investigators have previously reported that the HOX gene signature is particularly associated with NPM1 mutant AMLs. 20, 26, 27 Our study found that DNMT3A mutant AMLs without NPM1 mutations did not present this For personal use only. on April 16, 2017 . by guest www.bloodjournal.org From HOX gene signature; that is, HOX genes were not overexpressed in those AMLs (supplemental Figure 5) . Furthermore, HOX gene overexpression was also found in DNMT3A wild-type /NPM1 mutant AMLs. 20, 26, 27 Importantly, Vassiliou et al 28 reported recently that expression of mutant NPM1 in the myeloid compartment, using a NPM1-mutant knock-in mouse model, was associated with a strong up-regulation of HOX genes. Therefore, the role for mutated DNMT3A in aberrant control of HOX genes remains unclear. DNMT3A mutant / NPM1 mutant compound mice should further clarify what the effect of mutant DNMT3A is in myeloid progenitors and how it may affect HOX gene expression in the context of NPM1 mutations.
Currently, patient age, cytogenetics, and mutations in CEBPA, FLT3, and NPM1 at diagnosis are main prognostic factors in AML. [29] [30] [31] In line with recently published data, our data suggest a prognostic effect of DNMT3A mutant in AML. [14] [15] [16] We therefore propose to implement DNMT3A mutation analysis in the routine of the molecular diagnostics of human AML.
